Quantification of anti-fertility compound-Diosgenin concentration in the fenugreek seeds aqueous extrac (FSA)

This study aims to build a standardization method for preparation of effective powder from FSA and to quantify diosgenin in FSA. Methodology: One kg of FS were used in this study. Setting: BMS, KOM and KOP, IIUM Kuantan campus. FS were washed with distilled water to exclude any foreign matter, and were then air dried. FS-powder were put in distilled water in a ratio of 1 g of powder in 20 ml of distilled water and were shaken at room temperature for 24 hours. Ten mg of hydrolyzed extract sample was diluted in 10 ml volumetric flask with methanol for 15 minutes. Chromatographic estimation was performed using an equilibrated reverse phase Eclipse XDB-C18 column (particle size 5 μg, 4.6 mm x 150 mm). Results: One gram of FSA extract was hydrolyzed to produce sapogenins and 46.6% was recovered. A calibration curve that was constructed based on five dilutions of diosgenin standard at concentrations of 2, 5, 10, 20, 30 and 50 ppm produced a linear graft (r = 0.999). The concentration of diosgenin in FSA extract as calculated using the regression analysis was found to be 29.66 μg/ml, 13.81 % w/w on dried weight basis. Conclusion: Preparation and standardization of effective powder from FSA are the corner stone of many scientific researches in IIUM and Malaysia. Diosgenin is available in the FSA in adequate concentration. The adequate amount of diosgenin in the FSA will guide us to do further study in the way of preparation of a natural product that can be used in the field of reversible anti-fertility therapy

Identification of haptoglobin as a potential biomarker in young adults with acute myocardial infarction by proteomic analysis

Background: Acute myocardial infarction (AMI) molecular research in young adults is still limited. The aim of this study is to identify AMI proteomic biomarker(s) in young adults. Methods: This study comprised of two phases namely discovery and verification. In the discovery phase, proteins in the pooled plasma samples from young male adults between 18 and 45 years (10 AMI patients and 10 controls) were separated using two-dimensional electrophoresis. The protein spots that were expressed differently in the AMI patients were identified via matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. The plasma concentrations of these proteins were quantified using enzyme-linked immunosorbent assay during the verification phase (40 AMI patients and 80 controls). Results: Haptoglobin (Hp), apolipoprotein AI (Apo AI) and apolipoprotein AIV (Apo AIV) were up-regulated in the discovery phase. In the verification phase, the plasma concentration of Hp was significantly higher in AMI patients than the controls (P < 0.001). Logistic regression showed an association between Hp and AMI in young adults (odds ratio [OR] = 1.016, 95% CI: 1.002– 1.030, P = 0.025) independent of other AMI risk factors. Hp was significantly correlated with high sensitivity C-reactive protein (hs-CRP) (r = 0.424, P < 0.001). Conclusion: In young adults with AMI, plasma Hp concentrations were elevated and it is independently associated with AMI. A positive correlation with hs-CRP suggests Hp could be a potential biomarker of AMI in young adults

Proteomic profiles of young adults with acute myocardial infarction

Introduction: Proteomic profiling is essential in understanding the pathophysiological process of multifactorial diseases such as acute myocardial infarction (AMI). Despite the increasing incidence of AMI in young adults, proteomic-based study focusing on young AMI remains limited. This study aimed to examine the plasma proteomic profiles of young adults with AMI compared to control subjects. We also hope to identify disease-specific protein biomarkers that contribute to the development of AMI in the young. Methods: Pooled plasma protein from 10 AMI patients aged 18 to 45 years and 10 age, gender and racematched volunteers were separated using two-dimensional electrophoresis (2-DE). The spots proteins were analysed using the PD Quest analysis software. The spots proteins that were found to have been expressed differently between the two groups were identified by Matrix Assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF) Mass Spectrometry. Results: There were three differently expressed proteins namely Apolipoprotein AI (Apo AI), Apolipoprotein AIV (Apo AIV) and Haptoglobin (p < 0.05). The expressions of these proteins were found to be increased in young patients with AMI compared to control subjects. Conclusion: The up regulation of Apo AI, Apo AIV and Haptoglobin in AMI patients indicate their important roles in the development of atherosclerotic disease. Thus, Apo AI, Apo AIV and Haptoglobin are potential disease biomarkers for young AMI

Urinary Apolipoprotein A1 and its potential as a biomarker for coronary artery disease in young adults

INTRODUCTION: Very few studies have focused on exploring the utilisation of urinary protein biomarkers to improve the risk stratification of coronary artery disease (CAD) in young adults. Apolipoprotein A1 (ApoA1) as a primary constituent protein of Highdensity Lipoprotein (HDL) known to modulate cholesterol metabolism exhibits promising properties to be used as a protein biomarker, specifically for CAD in young adults. Thus, this study is aimed to evaluate the potential of urinary ApoA1 as a urinary biomarker of CAD in young patients with acute myocardial infarction (AMI). MATERIALS AND METHOD: This case-control study recruited 40 newly diagnosed AMI patients and 40 healthy control subjects aged 18–45. Urine samples were collected from all subjects. Once centrifuged, the supernatant was collected and stored at -80 °C until further analysis. The urinary concentration of ApoA1 was quantified using the ApoA1 Enzyme-linked Immunosorbent Assay (ELISA) kit according to the manufacturer's protocol. All subjects' risk factors were determined and documented, such as smoking status, Body Mass Index (BMI), blood pressure, plasma total cholesterol, and glucose levels. RESULTS: The mean age of AMI patients was higher than the controls; 37.1 1 ± 5.2 and 31.6 ± 8.1 years respectively. The mean urinary concentration of ApoA1 of AMI patients was significantly higher than the controls (12. 442 ± 3.571 vs. 10.067 ± 5.606 ng/ mL (p0.05). CONCLUSION: A significant elevation of urinary excretion of ApoA1 in AMI young adults demonstrated its potential use as a urinary protein biomarker for CAD in young adults

Risk factor profile of young adults with acute myocardial infarction: a preliminary finding

Acute myocardial infarction (AMI) is a major cause of death around the world. There are limited studies of risk factor profile in young adults with AMI. This study aimed to assess the risk factor profile of young adults with AMI at the emergency department of Hospital Tengku Ampuan Afzan (HTAA), Kuantan, Pahang. This is a preliminary result of young adults (age between 18 to 45 years old) who presented to the emergency department of HTAA

Urinary apolipoprotein A1 and its potential as a biomarker for coronary artery disease in young adults

INTRODUCTION: Very few studies have focused on exploring the utilisation of urinary protein biomarkers to improve the risk stratification of coronary artery disease (CAD) in young adults. Apolipoprotein A1 (ApoA1) as a primary constituent protein of Highdensity Lipoprotein (HDL) known to modulate cholesterol metabolism exhibits promising properties to be used as a protein biomarker, specifically for CAD in young adults. Thus, this study is aimed to evaluate the potential of urinary ApoA1 as a urinary biomarker of CAD in young patients with acute myocardial infarction (AMI). MATERIALS AND METHOD: This case-control study recruited 40 newly diagnosed AMI patients and 40 healthy control subjects aged 18–45. Urine samples were collected from all subjects. Once centrifuged, the supernatant was collected and stored at -80 °C until further analysis. The urinary concentration of ApoA1 was quantified using the ApoA1 Enzyme-linked Immunosorbent Assay (ELISA) kit according to the manufacturer's protocol. All subjects' risk factors were determined and documented, such as smoking status, Body Mass Index (BMI), blood pressure, plasma total cholesterol, and glucose levels. RESULTS: The mean age of AMI patients was higher than the controls; 37.1 1 ± 5.2 and 31.6 ± 8.1 years respectively. The mean urinary concentration of ApoA1 of AMI patients was significantly higher than the controls (12. 442 ± 3.571 vs. 10.067 ± 5.606 ng/ mL (p0.05). CONCLUSION: A significant elevation of urinary excretion of ApoA1 in AMI young adults demonstrated its potential use as a urinary protein biomarker for CAD in young adults

Plasma haptoglobin as a potential biomarker for coronary artery disease in young hypertensive adults

Uncontrolled hypertension is one of the recognized risk factors for coronary artery disease (CAD) in young adults, commonly underestimated owing to the young age. A novel biomarker to improve CAD risk assessment and hypertension management should be identified for this cohort. Thus, we had conducted a study to investigate plasma concentration and the role of haptoglobin in young hypertensive adults in the establishment of premature acute myocardial infarction (AMI). MATERIALS AND METHODS: A total of 120 male adults aged between 18 to 45 years enrolled into this cross-sectional study, divided into control, hypertensive, and acute myocardial infarction (AMI) groups. Blood samples were collected from all subjects, plasma concentrations of haptoglobin measured using enzyme-linked immunosorbent assays, and other CAD risk factors including high sensitivity C-reactive protein (hs-CRP) levels were analyzed. RESULTS: Plasma concentration of haptoglobin in the AMI group was the highest compared to hypertensive and control group (290.63±99.90 vs. 208.47±112.93 vs. 170.02±108.11 ng/ml, p<0.006). There was a significant association between AMI and plasma haptoglobin concentration in hypertensive subjects independent of other known CAD risk factors (OR: 0.985, 95% CI 0.973-0.997, p=0.017). There was positive correlation between plasma haptoglobin and hs-CRP (r=0.0370, p<0.001). CONCLUSION: Plasma haptoglobin is a potential biomarker to identify young hypertensive adults who are at risk of developing CAD

Optimization of a two-dimensional electrophoresis protocol for plasma proteomic profiling of obese schizophrenia patients

The proteomic approach is particularly effective for studying the association between obesity and schizophrenia. It allows for a comprehensive analysis of the complete proteome, leading to substantial breakthroughs in biomarker discovery and drug development. Isoelectric focusing (IEF) and SDS-PAGE procedures are combined in the proteomic approach known as twodimensional electrophoresis (2-DE), which separates proteins according to their isoelectric point and mass. This study aimed to investigate optimized conditions for the 2-DE technique by focusing on the selection of an immobilized pH gradient (IPG) strip. Protein extraction was performed on pooled plasma samples from 10 obese schizophrenia patients. The extracted protein samples were loaded onto two different pH (7 cm) IPG strips. The pH ranges between (I) 3 – 10 and (ii) 4 – 7. IEF was conducted following the PROTEAN IEF Cell System protocol, followed by SDS-PAGE. The resulting gels were stained with BioSafe Coomassie stain and washed with milliQ water. The stained gels were scanned, and the images were analyzed using PD Quest software. High-abundance proteins with a molecular weight range of 60 – 80 kDa were detected on both IPG strips. The results showed that using a pH 3 – 10 IPG strip, 245 protein spots were detected and distributed throughout the gel, with a notable concentration in the middle. Whereas using a pH 4 – 7 IPG strip resulted in the detection of 321 protein spots, indicating a higher quantity of protein spots with increased intensity. This is attributed to the improved fractionation of proteins resulting from the narrower and more focused pH range. Thus, it can be inferred that utilizing this pH range will yield optimal outcomes in protein separation and analysis. This study suggests selecting a pH 4 – 7 IPG strip is the recommended choice to achieve enhanced resolution and precise detection of protein spots in plasma samples from obese schizophrenia patients when employing the 2-DE method

Schizophrenia and apolipoprotein: a 10-year bibliometric analysis

Introduction: Schizophrenia is a chronic and complex mental disorder that significantly impacts one’s quality of life. The expansion of proteomic studies over the past decade offers a better understanding of the underlying pathophysiology of schizophrenia and the formulation of a protein targeted therapeutic approach. This study aimed to conduct a bibliometric analysis on the role of apolipoprotein as a biomarker in schizophrenia to provide a summary of its chronicle, present state and to identify potential future research directions. Materials and method: Publications on the association between schizophrenia and apolipoprotein were retrieved from the Scopus database using the search terms “schizophrenia” and “apolipoprotein”. Only original or review articles in English published between 2013 and 2023 were included. The bibliometric analysis was carried out using the R software packages Bibliometrix and Biblioshiny. Results: The filtered search identified 89 documents (80 original articles and 9 review articles) that generally showed an increasing trend with an annual growth rate of 10.31 percent. There were 580 authors that contributed to this field, with an average of eight to nine people co-authoring each paper. Altogether, 64 journals contributed to this field, with Neuropsychiatric Disease and Treatment, Frontiers in Psychiatry, and Translational Psychiatry being the three most productive. China leads in scientific production, followed by the Netherlands and the United States. In terms of country collaboration, the United Kingdom and Germany had the highest level of collaboration. The important keywords in the clusters were schizophrenia, biomarkers, proteomics, apolipoprotein E, antipsychotic drugs, bipolar disorder, and obesity. According to the thematic evolution analysis, apolipoprotein E has been frequently discussed and associated with schizophrenia and antipsychotic drugs. Conclusion: The association between schizophrenia and apolipoprotein has grown in significance over the past decade. Our findings highlight the potential role of apolipoprotein E in the establishment of schizophrenia and warrant further exploration